ARCHIVES

Second-Generation CML Drugs Show Promise For Frontline

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

NCI Shakeup Possibilities Grow; Marc Lippman To Head Lombardi Center; DCT Could Lose CTEP

March 11, 1988

Caplan: NEJM Should Go “The Extra Moral Mile”

January 9, 2009

AACR Urges FDA To Speed Approval of Therapies for Precancerous Lesions

November 15, 2002

In Brief: ACS Appoints Directors For Government Relations And Grassroots Development

April 25, 1997

NCCN and Pfizer Issue RFP In Renal Cell Carcinoma Or Hematologic Malignancies

October 25, 2013

NCI CTEP-Approved Trials For the Month of October

October 31, 2014